LMU recognizes Ethos Veterinary Health and Mass Vet as Distinguished Clinical Affiliate

, ,

This article was originally published in the Citizen Tribune,  

Lincoln Memorial University-College of Veterinary Medicine (LMU-CVM) recognized Ethos Veterinary Health and the Massachusetts Veterinary Referral Hospital (Mass Vet), with the Distinguished Clinical Affiliate Award in recognition of the vital role the clinical partner played in preparing LMU-CVM graduates. Dr. Beth Eisenberg, veterinary criticalist for Ethos Veterinary Health and a veterinarian for Mass Vet, accepted the award at the LMU-CVM Commencement Ceremony on May 18 in Harrogate, Tennessee.

“With our distributive clinical model, we’ve been honored to work with many outstanding veterinarians and veterinary practices,” said LMU-CVM Vice President and Dean Jason Johnson. “Ethos prioritizes education, and we are proud of our partnership with this outstanding organization.”

Ethos owns and operates several practices throughout the United States including Mass Vet, located in Woburn, Massachusetts. Over the last two years, Mass Vet has provided 31 four-week rotations of exceptional clinical and educational experiences for 17 LMU veterinary medicine students. The students who have rotated through Mass Vet rated the experience at the top of all clinical affiliate experiences offered, and students highly recommend this program to future classes.Eisenberg provided the leadership to establish and oversee the Ethos Mass Vet LMU-CVM clinical partnership. She is part of Ethos learning and development team and is a diplomat of the American College of Veterinary Emergency and Critical Care.

“Dr. Eisenberg has shown a personal keen interest in the growth and learning of our students, and always welcomes our students to her practice,” said Johnson. “She and her Mass Vet associates have done a wonderful job challenging, educating and preparing each student on their clinical journey and for life post-graduation.”

LMU-CVM’s hybrid distributed community-based educational model allows premier practices and institutions to participate in the education of future graduates. Well-qualified fourth-year veterinary students rotate through select, high-quality clinical affiliate locations where they obtain real-world learning experiences from highly qualified veterinarians. It allows for a mutually beneficial collaborative partnership between the veterinary college and community professionals.

Read the article on the Citizen Tribune

July Fourth Pet Safety


Written by Jacquelyne Wheat and Kristen Aberly

There are a lot of things to think about when preparing for the Fourth of July. What barbecue to go to, who’s coming over, what kind of plans will you have? Among all of the important Fourth of July preparations, one of the most important, yet the most overlooked, is keeping your pet happy and safe! Hopefully some of the tips below can help you when getting ready for the holiday.


  • Keep a collar on your pet. Did you know that July 5th is one of the busiest days for animal shelters? There is a 30% increase in lost pets between July 4th and July 6th. On average, only 14% are returned to their owners. Keep a collar on them and be on the lookout throughout the day!


  • Leave them at home/keep them inside. Crowded holiday festivities and fireworks displays can scare your pet and cause them to run off to get away from the chaos. Either keeping them inside if you’re having company over or leaving them at home if you’re heading out are your best options to make sure your pet does not run off!


  • Update their microchip information. Another step to take just in case your pet runs off is to update their microchip information! That way you know that they’ll be returned to the correct place if they happen to run away during the celebration.



  • Give them a safe space. Make your pet feel safe if you’re leaving them at home. Give them a space of their own to hide from the noises or keep them in a crate. Something else that can really help with taking away that fear they may have is to drown out the noise of fireworks with music, TV volume, or ambient sound.


  • Skip the celebration. Although many of us have plans on the Fourth, a great option for keeping your pet happy and safe is to skip the celebration completely, or to come home early. Sometimes your presence makes all the difference to them!


  • Keep them busy. No matter if you’re staying home, having company over, or leaving, keeping your pet busy with treat toys like Kongs can help to distract them from any party noise or fireworks that may be going on outside.


  • Purchase anxiety reducing products. Employ products that help to alleviate anxiety like anxiety wraps! These are a fabric tool that increases the positive effects of sensations that are sent by the brain receptors. Another product to think of are Thundershirts. These apply maintained pressure to calm your pet’s frustrated nerves. You can find these at your local pet store!


Be sure to talk to your veterinarian before the start of the holiday and ask your vet about options if your pet’s anxiety is especially severe. There are many options to relieve their stress, whether it be with medication, anxiety wraps, or just your presence alone.

Continued Growth for Ethos Veterinary Health

, ,

Ethos Veterinary Health Announces Continued Growth With The Addition of Two Hospital Groups

WOBURN, Mass., June 25, 2019 /PRNewswire:  Ethos Veterinary Health (Ethos), a leading independent veterinary health company, today announced the addition of two hospital groups: Wisconsin Veterinary Referral Center (WVRC), with three locations in Wisconsin, and Pet Emergency & Specialty Center of Marin (PESCM), located in San Rafael, Calif. The two entities substantially add to Ethos’ hospital network. WVRC extends Ethos’ Midwest footprint into Southern Wisconsin, and PESCM adds to Ethos’ existing presence in Northern California.

“We are excited to have these culturally aligned, successful teams join Ethos. The addition of WVRC and PESCM allows us to expand our network and the patient-focused medical care we believe in,” said Ames Prentiss, CEO of Ethos. “Both of these practices are well-established, professionally managed and highly respected in the industry.”

For WVRC and PESCM, joining Ethos means being able to take advantage of systems and programs they may not have had access to before.

“PESCM is excited to join an organization that honors and perpetuates our practice legacy while giving our team access to VetBloom, an enhanced educational and training platform, as well as a conduit for talent acquisition and proven best practices in the emergency/specialty space,” said Chris Rodi, DVM, Managing Partner at PESCM.

John Beltz, DVM, co-owner and Hospital Administrator of WVRC, added, “Dr. Jeff Meinen and I have known the Ethos team for many years, and we have a high degree of respect and confidence in their goals and mission. We chose to partner with and are glad to be part of Ethos as they strive to maintain the same high quality and ethical veterinary care we provide, while allowing us to leverage their size and scale for group efforts. Their commitment to the veterinary ethos is demonstrated not only in their words, but in their organizational structure, decision-making and actions.”

WVRC and PESCM also add to Ethos’ already extensive caseload. Over 300,000 patients are treated annually in Ethos hospitals. This allows for large clinical trials that generate data quickly, which in turn helps scale scientific innovation, an important priority for Ethos. This priority has seen significant momentum in 2019 with the completion of the CHAMP (Canine Hemangiosarcoma Molecular Profiling) Study – the first-ever, nationwide, multicenter, prospective study of Canine Splenic Hemangiosarcoma. In addition, the development of the ePARR test, a highly accurate test for the diagnosis of canine lymphoma, was announced in the second quarter of this year.

“Adding hospitals that share our vision of advancing veterinary medicine is a key focus for Ethos over the coming years,” said Brian Cassell, DVM, Chief Strategy Officer of Ethos. “We welcome the opportunity to speak with interested hospitals.”

# # #

For more info please contact info@ethosvet.com.

About Ethos Veterinary Health
Ethos is a veterinary health company with hospitals across the U.S. providing advanced medical care for pets. Our approach includes a focus on transformative science, continuous learning and growth for team members, and collaboration. For more information, visit ethosvet.com.

Nadja Torling

Animal hospital readies move to new quarters


This article was originally published in the Eagle Tribune,  

LAWRENCE — A North Andover animal hospital is preparing its long-planned move to its new home on Route 114 in Lawrence to the Route 114 site of the previous Showcase Cinemas.

Bulger Veterinary Hospital will move to its new facility at 141 Winthrop Ave., the former site of Showcase Cinemas. Bulger plans to re-open on June 27, officials announced.

The move comes a year after the Showcase Cinemas building there was razed. A Starbucks with a drive-thru is already open at the location.

“We are grateful to have the opportunity to expand our business into the city of Lawrence and become part of the community. The mayor and the city have been so supportive in our efforts and we are thankful for their encouragement,” said Ames Prentiss, CEO of Ethos Veterinary Health a national chain of which Bulger Animal Hospital is part.

“We are proud of our history of high quality veterinary care for pet owners in the Merrimack Valley and are enthusiastic for the future in our new home,” said Prentiss, an Andover native.

The new 17,000-square-foot hospital includes five surgery suites, 20 exam rooms, a new, 64-slice CT scanner, severe waiting rooms, a dedicated waiting room just for felines and a larger emergency facility.

The animal hospital’s services will continue to include primary care, 24/7 emergency and critical care (365 days year), surgery, cardiology, internal medicine, ophthalmology, acupuncture, an exotics team and more, Bulger officials said.

The hospital already has 105 employees and could be hiring as many as 15 more as new services are added, officials said.

“We are excited to offer such a remarkable facility with advanced medical care to the pets we love as our own family members,” said Steve Isherwood, hospital director.

“I’ve been bringing my own pets here with my family since I was a child,” he said.

Once the hospital move is complete, Bulger’s North Andover location at 247 Chickering Road will close.

Lawrence Mayor Daniel Rivera congratulated Prentiss and his team on the move and thanked them for bringing their business to Lawrence.

The former Showcase Cinema site “sat vacant for far too long,” Rivera said. He credited Prentiss with turning the area into a premier site “that will improve the quality of life for our community for years to come.”

“Large-scale development projects like this are what help our community continue to thrive and I am thrilled to have Bulger Veterinary Hospital, the premier animal hospital of the Merrimack Valley, make Lawrence its home,” Rivera said.

A ribbon-cutting and grand opening ceremony is scheduled for Sept. 25.

Showcase Cinemas closed the last of its theaters on Route 114 in 2016. Prentiss bought the property about a year or so later.

Prentiss said previously he’d been searching for years for a new location for the growing practice.

Read the article on the Eagle Tribune website

Bulger Veterinary Hospital Relocates to New, State-of-The-Art Facility Enhancing its Ability to Care for Pets


Lawrence, Mass. — June 12, 2019  – Bulger Veterinary Hospital will move to its new location at the former Showcase Cinema site in Lawrence, Massachusetts, located at 141 Winthrop Avenue in Lawrence, MA  the last week of June. The move brings the highly recognized 60-plus year-old Bulger Veterinary Hospital 2 miles, from neighboring North Andover to Lawrence, creating an exceptional facility for veterinary care. The 17,000 square foot state-of-the-art hospital will feature five surgery suites, more than twice as many exam rooms (20 in total) as the former hospital, a new 64-slice CT scanner, several waiting rooms including a dedicated waiting room for cats, and a larger emergency facility.

Services will continue to include primary veterinary care, 24/7 emergency and critical care (365 days a year), surgery, cardiology, internal medicine, ophthalmology, acupuncture, an exotics team and more.

“We are excited to offer such a remarkable facility with advanced medical care to the pets we love as our own family members,” said Steve Isherwood, Hospital Director. “I’ve been bringing my own pets here with my family since I was a child” he said.

Ames Prentiss, CEO of Ethos Veterinary Health, said “We are grateful to have the opportunity to expand our business into the city of Lawrence and become part of the community.  The Mayor and the City have been so supportive in our efforts and we are thankful for their encouragement.” Prentiss, an Andover native whose father, John K. Prentiss, DVM, purchased Bulger Veterinary Hospital in 1979, added, “We are proud of our history of high quality veterinary care for pet owners in the Merrimack Valley and are enthusiastic for the future in our new home.”

With the little over one-year construction now complete, Bulger’s North Andover location will close. All current 105 employees will move to the new location and the workforce could grow by another 15 people as new services are added.

“I want to congratulate Ames and his team on the opening of their new, state of the art veterinary hospital,” said Mayor Dan Rivera. “I also want to thank them for bringing their business into Lawrence and transforming a site that sat vacant for far too long and turned it into a premier site that will improve the quality of life for our community for years to come. Large scale development projects like this are what help our community continue to thrive and I am thrilled to have Bulger Veterinary Hospital – the premier animal hospital of the Merrimack Valley – make Lawrence its home.”

STAY TUNED: A Ribbon cutting ceremony and grand opening event is scheduled for September 25, 2019!

# # #

About Ethos Veterinary Health

Ethos is a veterinary health company with hospitals across the U.S. providing advanced medical care for pets. Our approach includes a focus on transformative science, continuous learning and growth for team members and collaboration. For more information, visit ethosvet.com.


LexaGene Places its First Beta Prototype into Massachusetts Veterinary Referral Hospital

, , ,

Source: LexaGene Holdings Inc

BEVERLY, Mass., June 05, 2019 (GLOBE NEWSWIRE) — LexaGene Holdings, Inc., (OTCQB: LXXGFTSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, announced today that it has placed its first beta prototype into Massachusetts Veterinary Referral Hospital (Mass Vet) in Woburn, MA.  Mass Vet is one of 24 hospitals owned and operated by Ethos Veterinary Health.

“This placement marks a very significant milestone for the Company and for the diagnostics industry.  We have generated a long list of interested users who want to test our technology.  From this list, we selected Mass Vet to be our first site due to their reputation for being pioneers and thought leaders in veterinary medicine.  The doctors at Mass Vet are eager to test our cutting-edge technology to provide the best possible treatment for their patients,” said Dr. Jack Regan, CEO and Founder of LexaGene. “Following the placement at Mass Vet, we will continue placing our devices at various other sites throughout the United States as part of our ongoing beta test program. This will enable potential customers to experience the technology in their own facility so that they can compare LX-generated results to their standard testing methods. We are confident these users will quickly appreciate the benefits of our technology and this will help seed future sales.”

The beta LX prototype is expected to identify the presence of bacteria in the overwhelming majority of urinary tract infections.  In addition, the beta prototype will simultaneously screen samples for common antibiotic resistance factors providing veterinarians the information they need to select the best treatment for their patients.

“Emergency and critical care veterinarians are eagerly awaiting the commercialization of an accurate instrument that can identify the cause of an infection and whether any antibiotic resistance factors are detected.  We are very excited to have the opportunity to first test LexaGene’s technology.  It is amazing that their instrument returns results so quickly, as we are used to waiting 3 days to get results back.  Shortening the turn-around time for quality results will lead to much better patient care,” said Dr. Chand Khanna DVM, PhD, DACVIM (Onc), DACVP (Hon), Chief Science Officer of Ethos Veterinary Health and President of Ethos Discovery.

A video interview with Dr. Jack Regan regarding this news can be viewed here.

We are pleased to announce that LexaGene will host a webinar tomorrow, Thursday, June 6th at 11 AM EST to provide an overview of the Company.  The webinar signup can be accessed at this link.

To be added to the LexaGene email distribution list, please subscribe on the Company website.


About LexaGene Holdings Inc.
LexaGene is a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers for on-site rapid testing in veterinary diagnostics, food safety and for use in open-access markets such as clinical research, agricultural testing and biodefense. End-users simply need to collect a sample, load it onto the instrument with a sample preparation cartridge, and press ‘go’. The LX Analyzer delivers excellent sensitivity, specificity, and breadth of detection and can process multiple samples at a time, in an on-demand fashion, returning results in about 1 hour. The unique open-access feature is designed for custom testing so that end-users can load their own real-time PCR assays onto the instrument to target any genetic target of interest.

About Ethos Veterinary Health
Ethos Veterinary Health is a veterinary health company with hospitals across the U.S. providing advanced medical care for pets. Our approach includes a focus on transformative science, continuous learning and growth for team members, and collaboration. For more information, ethosvet.com.

Media Contacts
Nicole Ridgedale
Director of Corporate Marketing, LexaGene
800.215.1824 ext 206

Investor Relations
Jay Adelaar
Vice President of Capital Markets, LexaGene
800.215.1824 ext 207

New study boasts 90% accuracy when using PARR to diagnose canine lymphoma

, , ,

Article originally published in NEWStat, an American Animal Hospital Association Publication 

Written by Tony McReynolds

Who measures the measurements? Who diagnoses the diagnostics? In short, who assays the assays?

Veterinarians have been using polymerase chain reaction for antigen receptor rearrangement (PARR), a readily available molecular assay that helps diagnose some kinds of canine lymphoma, for years. But no one really knew how accurate those assays were—because none have undergone a truly rigorous benchmarking study to determine the accuracy of PARR assays in general, regardless of the manufacturer.

Until now.

In a study published in the Journal of Veterinary Internal Medicine, Ethos Veterinary Health, Ethos Discovery, and the Translational Genomics Research Institute (TGen) found that their version of the test, called ePARR, was more than 90% accurate among a range of lymphoma sample types.

The results of the ePARR test study are based on an analysis of 180 dogs with cancer. The researchers used ePARR to confirm whether the dogs in the study had lymphoma and then to determine what type they had.

“We’re very excited about it,” Chand Khanna, DVM, PhD, DACVIM (Oncology), DACVP (Honorary), told NEWStat. Khanna is chief science officer of Ethos Veterinary Health, president of Ethos Discovery (a 501(c)3 independent not-for-profit incubator of scientific innovation), and co-senior author of the study.

Khanna emphasized that ePARR is not a new kind of assay but rather a new brand of assay, and the way it works to diagnose lymphoma isn’t different from what’s currently out there. He said the big takeaway here is the accuracy of the new study, which he calls “very rigorous.” He pointed out that the sheer number of dogs tested “well exceeds what has been done” in previous studies.

“What’s new is that doctors can offer [PARR assays] with a greater confidence in the performance of the assay than was possible before,” Khanna said.

Most dogs with lymphoma can be easily diagnosed using a simple microscopic evaluation of cells taken from the lymph node, so PAAR isn’t a first-line diagnostic test. However, a small minority of dogs yield tissue samples that display unusual features under the microscope, which makes some clinicians hesitant to begin treatment for lymphoma. In those cases, Khanna said, “you need a much more rigorous confirmatory test.”

PAAR, for example.

NEWStat asked Barbara Biller, DVM, DACVIM, retired associate professor of oncology at the Flint Animal Cancer Center at Colorado State University and practicing veterinarian at Boulder Road Veterinary Specialists in Lafayette, Colorado, what the study meant for veterinarians dealing with suspected cases of canine lymphoma.

“It’s further validation of [PARR],” Biller said. “We don’t need it to diagnose most cases of lymphoma but when we do need it, it can be really helpful. [The study clears up] some of the questions we have as far as how accurate it is for different samples.”

“This is the kind of data we need in this profession,” Biller added. “You have an organized, systematic evaluation of a technique. And it’s really good to see that kind of research.”


Read the article on NEWStat

TGEN-Ethos Study Underscores Need for Setting High Standards in Veterinary Cancer Diagnostics

, , , , ,

Written by Steve Yozwiak

PHOENIX, Ariz. — May 21, 2019 — Ethos Veterinary Health, Ethos Discovery, and the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, announced today that they have developed a highly accurate test for the diagnosis of canine lymphoma.

In a study published in the Journal of Veterinary Internal Medicine (JVIM), Ethos and TGen found that their test, called ePARR, was more than 90 percent accurate among a range of lymphoma sample types (link to the complete JVIM article is below).

TGen conducted genetic analysis of more than 180 dogs with naturally occurring cancer to confirm if they had lymphoma, and then determine exactly what type of lymphoma, which is a common and aggressive cancer in dogs.

“An ongoing need exists for robust validation of molecular diagnostics in veterinary medicine. This study is an example of exhaustive validation of one such molecular test,” said Dr. Will Hendricks, an Assistant Professor in TGen’s Integrated Cancer Genomics Division, and one of the study’s co-senior authors. “Overall, ePARR is more than 90 percent accurate across sample types and diagnostic settings.”

The study authors suggest that such tests could be even more accurate if testing facilities adopted more uniform testing techniques, established uniform high performance standards, and made their results more readily available to the general research community.

“In the veterinary diagnostic area, there is a need for methodological consistency and transparency. Each lab has their own methods for how to run the same test,” said Dr. Chand Khanna, Chief Science Officer of Ethos Veterinary Health, and also a co-senior author of the study. “Our validation of ePARR included over 180 dogs and a broad diversity of sample types, including cell pellets, air dried aspirates, and formalin-fixed paraffin-embedded tissues.”

Shukmei Wong, who is a TGen Senior Research Associate in the Hendricks Laboratory, who conducted the study experiments, and is a co-author of the study, said: “I hope this paper will inspire more reporting of assay methods and metrics, and help drive the creation of reference standards and more consistent protocols in diagnostics in veterinary medicine.”

Dr. Sam Stewart, Science Commercialization Fellow at Ethos Veterinary Health, agrees:

“It is truly unique to see such complete rigorous validation of a molecular assay in this field, and we hope this standard of transparency and quality will be followed by others. As a Critical Care doctor, I am proud to offer this high level of quality in a diagnostic assay to my patients.”

Molecular level investigations into dog DNA could someday not only improve the health of dogs with cancer, but also help contribute to a better understanding of cancer in humans, as well.

This study was funded by non-profit Ethos Discovery, which is evaluating options to make the ePARR test available to veterinarians and pet owners.

The study — Polymerase Chain Reaction for Antigen Receptor Rearrangement (PARR): Benchmarking performance of a lymphoid clonality assay in diverse canine sample types — was published April 2 in the Journal of Veterinary Internal Medicine.

No dogs were harmed during this research. Only tissue samples from pet dogs with naturally occurring cancers were examined.


Related Links:

# # #

About Ethos Veterinary Health

Ethos is a veterinary health company with hospitals across the U.S. providing advanced medical care for pets. Our approach includes a focus on transformative science, continuous learning, growth for team members, and the development of collaborative relationships. For more information, visit ethosvet.com.

About Ethos Discovery

Ethos Discovery is a 501(c)(3) non-profit incubator of scientific innovation that seeks to improve health outcomes in pets and humans with complex medical problems, including cancer. For more information, please visit ethosdiscovery.org.

About TGen, an affiliate of City of Hope

Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life-changing results. TGen is affiliated with City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases: www.cityofhope.org. This precision medicine affiliation enables both institutes to complement each other in research and patient care, with City of Hope providing a significant clinical setting to advance scientific discoveries made by TGen. TGen is focused on helping patients with neurological disorders, cancer, diabetes and infectious diseases through cutting-edge translational research (the process of rapidly moving research toward patient benefit). TGen physicians and scientists work to unravel the genetic components of both common and complex rare diseases in adults and children. Working with collaborators in the scientific and medical communities worldwide, TGen makes a substantial contribution to help our patients through efficiency and effectiveness of the translational process.

For more information, visit: www.tgen.org. Follow TGen on Facebook, LinkedIn and Twitter @TGen

Media Contact at TGen:
Steve Yozwiak
TGen Senior Science Writer

Clinical Trial: To evaluate a new therapy for cats with anemia due to chronic kidney disease

, ,

Ethos Veterinary Health is conducting a fully funded, FDA-regulated study to evaluate new therapy for cats with anemia due to chronic kidney disease.

We are currently enrolling cats in a study at a number of our hospitals involving the use of a unique gene therapy product. Products based on similar technologies (but not for this indication) are approved for use in human medicine in the U.S. and Europe, but this type of novel product has not yet been used for treating cats, making this an exciting treatment option.

Study Eligibility and Details:

  • Cats must be at least two years old and weigh at least 2 kg.
  • Eligible patients must have IRIS staged CKD and hematocrit of <28%.
  • The treatment is administered once by intramuscular injection at the beginning of the study (Day 0) and cats are monitored regularly for 70 days thereafter.
  • The study will include a placebo treatment group. Cats will be enrolled at a ratio of one placebo-treated cat for every four active-treated cats. Although the cats assigned to the placebo treatment group may not show improvement of their signs of anemia, they will still receive the benefit of free veterinary care and laboratory testing during the study.
  • Cats will receive physical exams, regular clinical pathology assessments and treatment at no charge to the client over the period of their participation in the study.
  • Owners who comply with study requirements will be compensated for costs associated with study.

Clinical Study for cats with chronic kidney disease

Enroll Today:

If you are interested in participating in this study, please refer to the list below and call the Ethos Veterinary Health hospital near you to learn more, or to schedule an appointment for a consult.

  • Boston West Veterinary Emergency & Specialty, Natick, MA: Dr. Hathaway Fiocchi, 508-319-2117
  • Bulger Veterinary Hospital, North Andover, MA: Dr. Annalisa Prahl, 978-682-9905
  • Capital District Veterinary Referral Hospital, Latham, NY: Dr. Shelley Smith, 518-785-1094
  • Massachusetts Veterinary Referral Hospital, Woburn, MA: Dr. Marion Haber and Dr. Kenneth Palladino, 781-932-5802
  • Port City Veterinary Referral Hospital, Portsmouth, NH: Dr. Karen Campbell and Dr. Tonya Brown, 603-433-0056
  • Premier Veterinary Group, Chicago, IL: Dr. Katie Simpson, 773-516-5800
  • Veterinary Specialty Hospital – Sorrento Valley, San Diego, CA: Dr. Kate Arnell, 858-875-7500
  • Vista Veterinary Specialists, Sacramento, CA: Dr. Nathan Bailiff, 916-231-4445


AAHA, VetBloom to Launch Exclusive AAHA Member Learning Platform

, , ,

LAKEWOOD, Colorado – April 30, 2019 – In a move that brings a veterinary industry leader in online CE together with the only association to accredit companion animal hospitals in North America, VetBloom and the American Animal Hospital Association (AAHA) are excited to announce the upcoming launch of the AAHA | Learning platform.

Provided as an exclusive AAHA member benefit, the new platform will be powered and hosted by VetBloom, a digital learning ecosystem from Ethos Veterinary Health (Ethos). At launch, it will include access to more than 50 hours of non-sponsored RACE-approved technical CE for veterinarians and technicians. But that’s only the start.

With courses available in a variety of formats ranging from interactive case-based learning modules and virtual simulations to podcasts, webinars, and more, VetBloom sets the industry standard for creating innovative and engaging content using cutting-edge learning technologies. The collaboration will open the door for AAHA to provide its own industry-leading educational resources to more than 4,400 accredited hospitals across Canada and the United States in fresh, relevant, and transformative ways.

“We couldn’t be more thrilled to be working with such an innovative and forward-thinking organization,” says AAHA Chief Executive Officer Michael Cavanaugh, DVM, DABVP (Emeritus). “VetBloom’s overall pedagogical approach combined with their aptitude for applying cutting-edge technologies in an easy-to-use and accessible manner makes them a true leader in the online learning space.”

Additional AAHA | Learning platform benefits include:

  • Continued access to high-quality existing AAHA CE, including AAHA’s guidelines
  • The option to upgrade to a premium-level subscription that provides access to hundreds of hours of CE for veterinarians and technicians as well as state-of-the-art, advanced courses
  • An easy-to-use, mobile-friendly interface and user experience that enables AAHA members to access their CE directly from their AAHA account
  • Customer support directly through the knowledgeable AAHA team

While these benefits will be available when the platform launches, new feature additions will be ongoing and content updates will occur regularly.

“We’re tremendously excited to be partnering with an industry leading organization such as AAHA,” says VetBloom founder and Ethos Chief Knowledge Officer Patrick Welch, DVM, MBA, DACVO. “The AAHA and VetBloom teams share a passion for learning and growth, and this collaboration provides us with the opportunity to develop a learning ecosystem that makes a truly meaningful impact for the veterinary industry.”

The AAHA Learning platform will launch in July.

For more information about the American Animal Hospital Association, visit aaha.org.


About AAHA

The American Animal Hospital Association is the only organization that accredits companion animal practices throughout the United States and Canada according to high standards of veterinary care. AAHA-accredited hospitals are recognized among the finest in the industry and are consistently at the forefront of advanced veterinary medicine. Pet owners look for AAHA-accredited hospitals because they value their pet’s health and trust the consistent, expert care provided by the entire healthcare team.

About VetBloom

VetBloom is an innovative learning ecosystem featuring the expertise of the finest veterinary professionals in the industry, along with cutting-edge, online instruction. Team members learn through direct and virtual instruction, interactive case-based scenarios and 3D simulations. VetBloom allows veterinary professionals to advance their skills from anywhere in the world. For more information visit vetbloom.com.

About Ethos

Ethos Veterinary Health is a veterinary health company with hospitals across the U.S. providing advanced medical care for pets. Our approach includes a focus on transformative science, continuous learning and growth for team members and collaboration. For more information, visit ethosvet.com.